

Nadeem Abu-Rustum, MD, is Chief of the Gynecologic Oncology Service in the Department of Surgery at Memorial Sloan Kettering Cancer Center, where he also serves as Vice-Chair for Technology Development. Additionally, he is the Avon Chair in Gynecologic Oncology and Professor of Obstetrics and Gynecology at Weill Cornell Medical College.

Dr. Abu-Rustum received his medical degree from the American University of Beirut in Lebanon. He completed his residency in obstetrics and gynecology at the Greater Baltimore Medical Center and a fellowship in gynecologic oncology at Memorial Sloan Kettering Cancer Center.

Dr. Abu-Rustum's clinical research focuses on surgical therapy for gynecologic cancers and innovative surgical approaches, including sentinel node mapping, improved localization of tumors, fertility-sparing surgery, and laparoscopy. He also has extensive experience in endometrial and cervical cancer and radical trachelectomy. In his current role at Memorial Sloan Kettering Cancer Center, he is actively involved in the development and improvement of minimally invasive techniques and oversees surgical research programs.

Dr. Abu-Rustum has served as a member of the Gynecologic Oncology Group Cervix Committee and the American College of Surgeons Committee on Emerging Surgical Technology and Education. He has authored or co-authored more than 200 publications and is co-author to numerous book chapters and three textbooks in gynecologic oncology.

Dr. Abu-Rustum is a member of the NCCN Cervical/Uterine Cancers Panel.

Jaffer Ajani, MD, is Professor of Medicine in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Dr. Ajani earned his medical degree from Government Medical College in India. He remained at the college to complete a rotating internship and a residency in general surgery and orthopedics. He continued his training at Pennsylvania State University with an internship and residency in family medicine. He later completed an internship and residency in internal medicine at Tulane University School of Medicine. He subsequently was awarded a clinical fellowship in medical oncology at The University of Texas MD Anderson Cancer Center, where he remained for a research fellowship in medical oncology. Dr. Ajani is board-certified in family medicine and internal medicine with a subspecialty in medical oncology.

Dr. Ajani's primary research interest is gastrointestinal oncology, with a focus on combined modality trials for gastric and esophageal cancers. Dr. Ajani has led numerous phase II and III randomized trials and has participated in cooperative groups. Additionally, he has written more than 300 peer-reviewed publications.

Dr. Ajani has participated in the International Society of Gastrointestinal Oncology (ISGIO) and currently serves as the editor of ISGIO's journal, *Gastrointestinal Oncology Research*.

Dr. Ajani is the Chair of the NCCN Gastric Cancer Panel.

Mahmoud Al-Hawary, MD, is Clinical Associate Professor in the Department of Radiology at the University of Michigan.

Dr. Al-Hawary received his medical degree from the American University of Beirut in Lebanon, where he also completed an internship and residency in diagnostic radiology. He continued his training with a fellowship in body imaging at the University of Michigan, where he subsequently remained as a faculty member.

Dr. Al-Hawary is part of a team that evaluates cancers. His primary clinical interests include small and large bowel diseases as well as benign and malignant pancreatic diseases. His research interests focus on body computed tomography and magnetic resonance imaging of hepatic, biliary, pancreatic, adrenal, and bowel malignancies.

Dr. Al-Hawary has published numerous peer-reviewed papers on the topics of inflammatory bowel disease and pancreatic cancer imaging. Additionally, he is involved in multiple national organizations, including the American College of Radiology, the Radiological Society of North America, the Society of Gastrointestinal Radiology/Society of Abdominal Radiologists, and the American Gastroenterology Association. He also serves as an ad-hoc reviewer for several prominent scientific publications, including *European Radiology*, *Cancer*, *Inflammatory Bowel Diseases*, and *Gastroenterology*.

Dr. Al-Hawary is a member of the NCCN Imaging Panel and the Imaging Sub-Committee of the NCCN Pancreatic Adenocarcinoma Panel.

Kenneth C. Anderson, MD, is the Kraft Family Professor of Medicine at Harvard Medical School and the Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor.

Dr. Anderson earned his medical degree from Johns Hopkins Medical School and a master's degree from Harvard University. He completed a fellowship and residency in internal medicine at Johns Hopkins Hospital. He then went on to complete a fellowship in hematology, medical oncology, and tumor immunology at Dana-Farber Cancer Institute.

Over the last three decades, Dr. Anderson's laboratory and clinical research studies have focused on multiple myeloma. He has developed laboratory and animal models of tumors in its microenvironment, which have allowed for both identification of novel targets and validation of novel targeted therapies. Dr. Anderson rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome.

Dr. Anderson is the recipient of many scientific and humanitarian awards, including the International Myeloma Waldenström's Award, the International Myeloma Foundation Robert A. Kyle Lifetime Achievement Award, the American Association for Cancer Research Joseph H. Burchenal Award, and the American Society of Hematology William Dameshek Prize. He was elected into the Johns Hopkins Society of Scholars, the Institute of Medicine of the National Academy of Sciences, and the Royal College of Physicians and of Pathologists (United Kingdom). Dr. Anderson received the American Society of Clinical Oncology David A. Karnofsky Award and the Hope Funds for Cancer Research Award of Excellence in Clinical Research. He has been the recipient of the Ron Burton Humanitarian Award, the Harvard Medical School Warren Alpert Foundation Prize, and the American Cancer Society Medal of Honor. Dr. Anderson also has received the Leonard P. Zakim Patient Advocacy Award, the Samuel Waxman Research Foundation David Workman Memorial Award, and the University of Miami Sylvester Cancer Center Annual Zubrod Memorial Award.

Dr. Anderson is a member of numerous professional societies and associations and serves on many committees and boards. He has authored a significant number of scientific publications and is a world-renowned lecturer.

Dr. Anderson is a member of the editorial board for the *Journal of the National Comprehensive Cancer Network (JNCCN)* and serves as the Chair of the NCCN Multiple Myeloma/Systemic Light Chain Amyloidosis/Waldenström's Macroglobulinemia Panel.

Pamela S. Becker, MD, PhD, is Professor of Medicine in the Division of Hematology at the University of Washington School of Medicine and Attending Physician at the University of Washington Medical Center and Seattle Cancer Care Alliance. She is a member of the Institute for Stem Cell and Regenerative Medicine and the Center for Cancer Innovation at the University of Washington. She also serves as an Associate Member of the Clinical Research Division at Fred Hutchinson Cancer Research Center.

Dr. Becker received her medical degree from the Harvard Medical School-Massachusetts Institute of Technology Health Sciences and Technology Program and her doctorate of philosophy - from the Harvard Graduate School of Arts and Sciences Program on Cell and Developmental Biology, Division of Medical Sciences. Dr. Becker completed an internship and residency in internal medicine at Beth Israel Hospital of Harvard Medical School. She also completed a post-doctoral hematology fellowship at Yale University School of Medicine. She is board-certified in in hematology.

Dr. Becker's clinical interests include acute leukemia, myelodysplastic syndrome, multiple myeloma, and hematopoietic cell transplant. Her laboratory and translational research focus on cell adhesion mediated chemotherapy drug resistance, development of individualized therapy for hematologic malignancies, and hematopoietic stem cell gene therapy.

Dr. Becker lectures regularly and has published 100 peer-reviewed journal articles, 18 book chapters and reviews, and several other publications including 18 articles while serving as a contributing editor of *The Hematologist*. She is a member of multiple professional organizations, including the American Society of Hematology, the American Society of Clinical Oncology, the American Society of Blood and Marrow Transplantation, the ISEH Society for Hematology and Stem Cells, the American Society for Gene Therapy, and the Southwest Oncology Group.

Dr. Becker is the Vice-Chair of the NCCN Myeloid Growth Factors Panel.

Therese Bevers, MD, is Professor of Clinical Cancer Prevention and Medical Director of the Cancer Prevention Center and Prevention Outreach Programs at The University of Texas MD Anderson Cancer Center.

Dr. Bevers received her medical degree and completed a family practice residency at the University of Texas Health Science Center at San Antonio. She is board-certified by the American Board of Family Practice.

In her role as medical director, Dr. Bevers has overseen the growth and program development of the Cancer Prevention Center—the first comprehensive clinical cancer prevention service program in the country—since its opening in 1996. Her clinical and research interests include breast cancer prevention, screening, diagnosis, and survivorship. She is actively involved in the development of clinical trials that examine the treatment and prevention of breast cancer.

Dr. Bevers is a member of several professional societies, including the Alliance for Clinical Trials in Oncology, the American Academy of Family Physicians, the American Cancer Society Leadership Council for the Gulf Coast Region, the American Society of Breast Disease, the American Society of Clinical Oncology, the American Society of Preventive Oncology, and the Southwest Oncology Group. Additionally, Dr. Bevers is the recipient of many awards including the Julie and Ben Rogers Award for Excellence in Prevention, the Kathryn S. Stream Award for Excellence in Women's Health, and the Faculty Achievement Award in Prevention.

Dr. Bevers chairs the NCCN Breast Cancer Screening and Diagnosis Panel and the NCCN Breast Cancer Risk Reduction Panel. She also is an editorial board member for the *Journal of the National Comprehensive Cancer Network (JNCCN)*.

Kirsten Bibbins-Domingo, PhD, MD, MAS, is the Lee Goldman, MD Endowed Chair in Medicine and Professor of Medicine and of Epidemiology and Biostatistics at the University of California, San Francisco (UCSF). She is the Director of the UCSF Center for Vulnerable Populations at San Francisco General Hospital, a research center focused on discovery, innovation, policy and advocacy, and community engaged research in populations at risk for poor health and inadequate healthcare. She is a board member of UCSF's Clinical and Translational Science Institute and Director of the Clinical and Translational Science Training Programs.

Dr. Bibbins-Domingo received her medical degree, doctorate of philosophy in biochemistry, and master's of advanced study degree in epidemiology and biostatistics from UCSF, where she also completed an internship, residency, and fellowship in internal medicine.

Dr. Bibbins-Domingo is a recognized expert in evidence-based prevention in both clinical and public health settings. She is the Chair of the US Preventive Services Task Force and has been a member for more than 5 years. She is an inducted member of the American Society for Clinical Investigation and the National Academy of Medicine.

Cybele Bjorklund, Distinguished Visitor/Senior Fellow, Georgetown University in Washington, D.C., is the former Democratic Staff Director for the Health Subcommittee on the Committee on Ways and Means in the United States House of Representatives. The Committee's health portfolio includes Medicare, selected provisions in the Affordable Care Act, private health insurance, and other health issues in the Internal Revenue Code. She was the senior health care advisor to Democratic members on the Committee from 2001 – 2015.

Ms. Bjorklund has been at the center of virtually every major Medicare debate since 1995. She had a leading role in the creation and enactment of the Affordable Care Act, and in the health information technology (IT) and comparative effectiveness research provisions enacted in the Economic Recovery Act of 2009.

Prior to her position with the United States House of Representatives, Ms. Bjorklund spent nearly four years as Senator Edward Kennedy's (D-MA) deputy staff director for health policy on the Health, Education, Labor and Pensions (HELP) Committee in the United States Senate. In this capacity, Ms. Bjorklund provided policy guidance during the development and enactment of the state Children's Health Insurance Program (CHIP), and developed and advanced a variety of legislative initiatives, including the Patients' Bill of Rights, medical privacy, HIPAA implementation, reauthorization of the Agency for Healthcare Research and Quality and other public health initiatives and insurance reform legislation.

From 1995-1997, she worked as a legislative aide on health and veterans' issues for Senate Democratic Leader Tom Daschle (D-SD), covering Medicare reform during the Balanced Budget Act debates of 1995-1997 and other issues. Before moving to Congress, Ms. Bjorklund was a Medicare and insurance policy analyst at the Health Care Financing Administration (now the Centers for Medicare and Medicaid Services) within the U.S. Department of Health & Human Services.

Ms. Bjorklund received a master's degree from The Johns Hopkins University's School of Hygiene and Public Health, with an emphasis on health policy and a concentration in law, ethics and policy, and a bachelor's degree in journalism from the School of Journalism at the University of Oregon. She currently serves on the Health Advisory Board for APCO Public Affairs and is a council member for the Gerson Lehrman Group. Ms. Bjorklund also is a member of the National Academy of Social Insurance and the Policy Advisory Committee for the Medicare Rights Center, and serves on the board of directors for the David A. Winston Health Policy Fellowship.

Sarah L. Blair, MD, is Clinical Professor in the Department of Surgery at the University of California, San Diego (USCD).

Dr. Blair received her medical degree from SUNY Buffalo School of Medicine in New York. She completed residencies at the University of Massachusetts Medical School and a surgical oncology fellowship at City of Hope National Medical Center, where she was honored as the Terrell McElligot Surgical Oncology Fellow. She is board-certified in general surgery.

Dr. Blair has extensive experience in cutting edge technologies, such as sentinel node staging for breast cancer, melanoma, and other soft tissue tumors. Her primary clinical and research interest is breast cancer. She has served as Principal Investigator (PI) or Co-PI for several multiple trials examining a pre-operative localization technique for surgical resection of non-palpable breast cancers by local injection of nanoparticles. As part of this research, Dr. Blair is developing a method for using advanced imaging techniques to ensure that all the tumor cells are removed during a cancer surgery. This method will allow for the precise removal of tumors and may eliminate the need for additional surgery or possible tumor treatment in the future.

Dr. Blair is a member of the NCCN Breast Cancer Panel.

Toby C. Campbell, MD, MSCI, is Associate Professor of Medicine in the Hematology-Oncology Section of the University of Wisconsin School of Medicine and Public Health. He is a thoracic medical oncologist, the Chief of Palliative Care, and the Program Director of the Hospice and Palliative Medicine Fellowship Training Program.

Dr. Campbell received his medical degree from the University of Virginia and completed his internal medicine residency at the University of Wisconsin Hospital and Clinics. He completed his master's degree in clinical investigation along with fellowships in medical oncology and palliative medicine at Northwestern University.

Dr. Campbell's clinical practice interests are in lung cancer, palliative care and high risk communication. His research interests are in shared decision making, empathy, models of delivering palliative care, and existential anxiety.

Dr. Campbell is a member of several professional organizations, including the American Society of Clinical Oncology, International Association for the Study of Lung Cancer (IASLC), and the American Association of Hospice and Palliative Medicine.

Robert W. Carlson, MD, is the Chief Executive Officer (CEO) at the National Comprehensive Cancer Network (NCCN). He joined NCCN as CEO in January 2013 following an esteemed history of leadership positions within the organization including, most notably, Representative to the NCCN Board of Directors, Chair of the Breast Cancer Guidelines Panel, Member and Founding Chair of the Breast Cancer Risk Reduction Guidelines Panel, and Chair of the Survivorship Guidelines Panel.

Prior to his appointment as CEO at NCCN, Dr. Carlson served as Professor of Medicine in the Division of Oncology and Stanford Medical Informatics at Stanford University Medical Center, as well as Medical Director of inpatient oncology and hematology at Stanford Cancer Institute.

Dr. Carlson is a graduate of Stanford University Medical School, and he completed his internship and junior residency in internal medicine at Barnes Hospital Group in St. Louis, Missouri before returning to Stanford University to complete his senior residency. He earned a bachelor of science with distinction from Stanford University, specializing in biological sciences. Dr. Carlson is board certified in medical oncology and internal medicine.

Dr. Carlson is a member of several medical societies, including American College of Physicians, American Association for Cancer Research, and the American Society of Clinical Oncology. Dr. Carlson lectures extensively and has authored or co-authored more than 140 articles, abstracts, and book chapters, which have appeared in publications such as the *Journal of the National Cancer Institute*, the *Journal of Clinical Oncology*, and *The Breast Journal*. He has served as Associate Editor of *Oncology* and the *Journal of the National Comprehensive Cancer Network (JNCCN)*.

From 2001 to 2012, Dr. Carlson was selected by *America's Top Doctors*; from 1994 to 2011, he was selected by *Best Doctors in America*; in 2008, he was presented with the National Physician of the Year Award for Clinical Excellence by Castle Connolly Medical, Ltd.; and in 2010, Dr. Carlson was given the Founding Collaborator Award by the Breast Health Global Initiative.

Daniel T. Chang, MD, is Associate Professor of Radiation Oncology at Stanford University. He is a member of Stanford Cancer Institute and Stanford Bio-X, an initiative dedicated to the supporting, organizing, and facilitating interdisciplinary research connected to biology and medicine.

Dr. Chang received his medical degree from Wayne State University in Detroit, Michigan. He completed an internship within the Oakwood Health System in Michigan, followed by a radiation oncology residency and chief residency at the University of Florida in Gainesville.

Dr. Chang specializes in radiotherapy for gastrointestinal malignancies, with a special interest in stereotactic body radiotherapy (SBRT) for liver tumors. His clinical work focuses on developing functional imaging as a means of determining treatment response with radiation. His research interest also include developing image-guided radiotherapy to improve radiation delivery for gastrointestinal cancers to reduce toxicity and improve disease outcome.

Dr. Chang is a member of several professional organizations, including the American Society for Radiation Oncology, the Radiological Society of North America, and the American Society of Clinical Oncology. He also serves as an ad-hoc editorial review for a number of prominent scientific publications, including the *Annals of Surgical Oncology*, *Cancer Chemotherapy and Pharmacology*, *Cancer*, and the *American Journal of Clinical Oncology*.

Dr. Chang is a member of the NCCN Hepatobiliary Cancers Panel.

Lanhee J. Chen, PhD, is the David and Diane Steffy Research Fellow at the Hoover Institution, Director of Domestic Policy Studies and Lecturer in the Public Policy Program at Stanford University, and an affiliate of Stanford's Freeman Spogli Institute for International Studies. His current research focuses on health policy, retirement security policy, campaigns and elections, and California policy and politics. Specifically, Dr. Chen's work in health policy has focused on Medicare, Medicaid, ERISA, and the impact of the Patient Protection and Affordable Care Act (PPACA) on states, private enterprises, and all parts of the health care economy.

Dr. Chen is a presidentially-appointed and Senate-confirmed member of the Social Security Advisory Board—an independent, bipartisan panel that advises the president, Congress, and the Commissioner of Social Security on matters related to the Social Security and Supplemental Security Income programs.

A veteran of several high-profile political campaigns, Dr. Chen has also served in government, the private sector, and academia. He currently advises the presidential campaign of Senator Marco Rubio and in 2014 was Senior Adviser on Policy to the National Republican Senatorial Committee (NRSC).

Dr. Chen was the policy director for the Romney-Ryan 2012 presidential campaign, as well as Governor Romney's chief policy adviser; a senior strategist on the campaign; and the person responsible for developing the campaign's domestic and foreign policy. He advised Romney on every major public policy challenge facing the United States and worked with a variety of stakeholders, including the congressional leadership, industry and business interests, and policy experts, to shape the campaign's issues agenda.

Dr. Chen also served as the deputy campaign manager and policy director of Steve Poizner's 2010 California gubernatorial campaign, the domestic policy director of Governor Romney's first presidential bid in 2008, and a health policy adviser to the Bush-Cheney reelection campaign in 2004.

In the Bush administration, Dr. Chen was a senior official at the US Department of Health and Human Services. His private-sector experience includes having been an associate attorney with the international law firm of Gibson, Dunn & Crutcher LLP, where he practiced business litigation. Dr. Chen was also the Winnie Neubauer Visiting Fellow in Health Policy Studies at the Heritage Foundation and worked as a health policy advocate for a major business group in Washington, DC.

At Stanford, Dr. Chen currently serves as a member of the Faculty Steering Committee at the Haas Center for Public Service. He has also been Lecturer in Law at Stanford Law School. An eight-time winner of Harvard University's Certificate of Distinction in Teaching, Chen's scholarship has appeared or been cited in several of the nation's top political science journals.

In 2015, Dr. Chen was honored as one of the POLITICO 50, a list of the "thinkers, doers, and visionaries transforming American politics." He earned a similar honor in 2012 when he was named one of POLITICO's "50 Politicos to Watch." Dr. Chen's writings have appeared in a variety of outlets, including The Wall Street Journal, the Los Angeles Times, and Bloomberg View. He frequently provides commentary on television networks including CNBC, CNN, FOX News, and MSNBC.

Dr. Chen frequently provides advice to companies and governmental entities on a wide range of contemporary public policy issues and is the founder and president of Launch Policy Strategies, a strategic consulting company. He is also Counsel at the law firm of Arent Fox LLP and a member of both the International Advisory Council and the Health Advisory Board at APCO Worldwide, an international public affairs and communications firm.

Dr. Chen also serves in a variety of leadership roles in nonprofits and community-based organizations. He is a Director of El Camino Hospital in the Silicon Valley, serves on the Board of Trustees of the Junior Statesmen Foundation and is on the Advisory Board of the Partnership for the Future of Medicare. Dr. Chen was recently elected to membership in the Committee of 100, an organization of prominent Chinese Americans.

Dr. Chen earned his doctorate of philosophy and master's of arts degree in political science from Harvard University, his juris doctor degree cum laude from Harvard Law School, and his bachelor of arts degree magna cum laude in government from Harvard College. He is a member of the State Bar of California.

Anne Covey, MD, is an attending radiologist at Memorial Hospital for Cancer and Allied Diseases and Associate Professor of Radiology at Weill Cornell Medical College.

Dr. Covey earned her medical degree from Columbia College of Physicians and Surgeons. She completed her residency in diagnostic imaging at Yale-New Haven Hospital and a fellowship in vascular interventional radiology diagnostic imaging.

Dr. Covey is known locally and nationally for her research in diseases of the liver. Her clinical and research interests include treatment of tumors in the liver using embolization and ablation as well as biliary interventions, such as cholangiography, biliary drainage, and internal stents.

Dr. Covey is a member of numerous professional societies and associations including the American College of Radiology, the Society of Interventional Radiology, and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE). She has authored or co-authored a significant number of scientific publications. Dr. Covey is Assistant Editor of the *American Journal of Roentgenology* and serves as a reviewer for several professional journals.

Dr. Covey is a member of the NCCN Hepatobiliary Cancer Panel.

Maria Dans, MD, is Director of Palliative Care Services at Siteman Cancer Center at Barnes-Jewish Hospital and Assistant Professor in the Division of Hospitalist Medicine, Department of Internal Medicine at Washington University School of Medicine in St. Louis, Missouri. Dr. Dans previously worked as a surgical intensive care physician at Washington Hospital Center in Washington, D.C.

Dr. Dans received her medical degree from Washington University School of Medicine. She completed a residency in internal medicine and fellowships in palliative medicine and critical care medicine at Stanford University. Dr. Dans is board-certified in internal medicine, with subspecialties in critical care medicine and hospice and palliative medicine.

Dr. Dans' clinical interests include in-patient care, patient safety, and hospice & palliative medicine. She currently serves as an associate editor for the American College of Surgeons ethics webpage.

Dr. Dans is the Chair of the NCCN Palliative Care Panel. She also serves as an editorial board member for the *Journal of the National Comprehensive Cancer Network (JNCCN)*.

John Fanikos, RPh, MBA, is Director of Pharmacy Services at Brigham and Women's Hospital (BWH) in Boston, Massachusetts. Mr. Fanikos also serves as Adjunct Professor of Clinical Pharmacy Practice at the Massachusetts College of Pharmacy (MCP) University. He earned his bachelor of science degree in pharmacy at MCP and his master's of business administration degree at Northeastern University. He completed an American Society of Health-System Pharmacists (ASHP)-accredited residency at BWH.

Mr. Fanikos has served in a number of different roles at BWH, including investigational drug pharmacist, inpatient and outpatient pharmacy supervisor, clinical preceptor, and pharmacy administrator. While fulfilling these roles, he has worked with patients on orthopedic, oncology, cardiology, and general medicine units. For the past 20 years, he has worked closely with the BWH Thromboembolism Research Group, and he has authored and co-authored many articles and textbook chapters on anticoagulant and antiplatelet medications. His research focus has been identifying and avoiding the problems and pitfalls of their use. Mr. Fanikos is a member of the NCCN Cancer-Associated Venous Thromboembolic Disease Panel. He serves as the treasurer and sits on the Board of Directors for the North American Thrombosis Forum (NATF), a non-profit organization that provides a platform for those interested in thrombotic disorders to enhance disease education, awareness, advocacy, research, and prevention. He also serves on the Board of Directors for the Hospital Quality Foundation (HQF). Similarly, the HQF is a 50C3 charitable organization dedicated to improving the quality of healthcare by supporting the development and delivery of education related to medical practice.

Mr. Fanikos is Past President of the Massachusetts Society of Health-System Pharmacists. Both his father and brother are pharmacists, which makes him aware of many of the issues challenging the medical professions today.

Elizabeth J. Fowler, PhD, JD, is currently Vice President for Global Health Policy at Johnson & Johnson where she is focused on delivery system and payment reform in the U.S. and health care systems and reform in emerging markets. Prior to joining Johnson & Johnson, Dr. Fowler was special assistant to President Obama on healthcare and economic policy at the National Economic Council. During the health reform debate in 2009-2010, she was Chief Health Counsel to Senate Finance Committee Chair, Senator Max Baucus (D-MT), where she played a critical role in developing the Senate version of the Affordable Care Act. She also played a key role in drafting the 2003 Medicare Prescription Drug, Improvement and Modernization Act (MMA).

Dr. Fowler has nearly 25 years of experience in health policy and health services research. She earned her bachelor's degree from the University of Pennsylvania, a doctorate of philosophy from the Johns Hopkins School of Public Health, where her research focused on risk adjustment, and a law degree (juris doctor) from the University of Minnesota. She is admitted to the bar in Maryland, the District of Columbia, and the U.S. Supreme Court. Dr. Fowler is a Fellow of the inaugural class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network.

Scott Gottlieb, MD, is a practicing physician and Resident Fellow at the American Enterprise Institute, a nonpartisan, not-for-profit institution dedicated to research and education on issues of government, politics, and economics. A leading expert in health policy, Dr. Gottlieb's work focuses on providing insights into the economic, regulatory and technological forces driving the transformation of healthcare today.

From 2005-2007, Dr. Gottlieb served as FDA Deputy Commissioner and before that, from 2003-2004, as a senior advisor to the FDA Commissioner and as the FDA's Director of Medical Policy Development. He left FDA in the spring of 2004 to work on implementation of the Medicare Drug Benefit as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services.

Dr. Gottlieb is a regular contributor to The Wall Street Journal, and has held editorial positions on the British Medical Journal and the Journal of the American Medical Association. He appears regularly as a guest commentator on the cable financial news channel CNBC. He serves as a board member to several life science companies and is a venture partner at the venture capital firm New Enterprise Associates.

Dr. Gottlieb is a Clinical Assistant Professor at the New York University School of Medicine. He completed a residency in internal medicine at the Mount Sinai Hospital in New York and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University, in Middletown, Connecticut, where he studied Economics.

William J. Gradishar, MD, is the Betsy Bramsen Professor of Breast Oncology in the Division of Hematology and Medical Oncology, Department of Medicine at the Feinberg School of Medicine at Northwestern University and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. He serves as Director of the Maggie Daley Center for Women's Cancer Care. He also has served as Chair of the Annual Lynn Sage Comprehensive Breast Cancer Symposium since its inception.

Dr. Gradishar received his medical degree from the University of Illinois Abraham School of Medicine. He later completed a residency and chief residency in internal medicine at Michael Reese Hospital and Medical Center and a fellowship in medical oncology at the University of Chicago. He is board-certified in internal medicine and medical oncology.

Dr. Gradishar has published in the area of breast cancer therapeutics, with a focus on new endocrine therapy, chemotherapy, and biologic agents. A Fellow of the American College of Physicians, Dr. Gradishar also is a member of the American Association for Cancer Research, the American Federation for Clinical Research, and the Association of Subspecialty Professors. He is a Fellow of the American Society of Clinical Oncology (ASCO) and past-Chair of ASCO's Nominating Committee, Professional Development Committee, Oncology Training Program Committee, and Communications Committee. He has served on the Committee on Cancer for the American College of Surgeons. Additionally, Dr. Gradishar serves as a consultant to the Oncology Drug Advisory Committee of the FDA. He has served on numerous study sections including NIH, NCI, ACS, Komen, and Alberta Cancer Board. Dr. Gradishar was awarded the Betsy Bramsen Endowed Chair of Breast Oncology at Northwestern University.

Dr. Gradishar is an editorial board member for numerous journals, including *Journal of Clinical Oncology*, *Oncology*, *Clinical Breast Cancer*, *Journal Watch*, *European Journal of Clinical and Medical Oncology*, and *Clinical Cancer Research*. He currently serves as Chair of the NCCN Breast Cancer Panel and as a member of the NCCN Breast Cancer Risk Reduction Panel.

Benjamin E. Greer, MD, is Professor of Gynecological Oncology at University of Washington Medicine. He also serves as Medical Director of the Seattle Cancer Care Alliance Network.

Dr. Greer received his medical degree from the University of Pennsylvania and completed a residency in obstetrics and gynecology at the University of Colorado Medical Center. He also participated in a Management Program in the School of Business Administration at the University of Washington. He is board-certified in obstetrics and gynecology with a subspecialty in gynecological oncology.

Dr. Greer specializes in the application of radiation therapy application to gynecologic cancers. His clinical research has significantly impacted women with gynecologic cancers. His work has been extensively published in prominent scientific journals, including *Cancer*, *The New England Journal of Medicine*, and *Gynecological Oncology*.

Dr. Greer is affiliated with a number of professional societies, including the American College of Obstetricians and Gynecologists, the American Gynecological and Obstetrical Society, the American Society of Clinical Oncology, the International Gynecologic Cancer Society, the Society of Gynecologic Oncologists, and the Washington State Medical Oncology Society.

Dr. Greer is Co-Chair of the NCCN Cervical/Uterine Cancers Panel and a member of the editorial board for the *Journal of the National Comprehensive Network (JNCCN)*. He also serves on the NCCN Affiliate Forum and Affiliate Research Consortium Advisory Board.

Leora Horn, MD, MSc, holds multiple positions at Vanderbilt University, including Associate Professor of Medicine in the Department of Hematology and Oncology, Clinical Director of the Thoracic Oncology Research Program, and Assistant Vice Chancellor for Faculty Development.

Dr. Horn received her medical degree from the University of Toronto, where she also completed her postgraduate training in internal medicine and medical oncology. She later received an award from the Canadian Association of Medical Oncology that funded a thoracic oncology fellowship which she completed at Vanderbilt University.

Dr. Horn's clinical practice focuses on the care of patients with lung cancer. Her research interests include experimental therapeutics and medical education. She is co-author of numerous scientific journal articles, book chapters, and manuscripts. She also serves as a reviewer for *Clinical Lung Cancer*, *Journal of Clinical Oncology*, the *Journal of Thoracic Oncology*, *Annals of Oncology*, and *The Clinical Teacher*.

Dr. Horn has received multiple honors and awards, most recently receiving the NCI Cancer Clinical Investigator Team Leadership Award. She is a member of multiple professional societies, including the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and the Royal College of Physicians and Surgeons of Canada.

Dr. Horn is a member of the NCCN Non-Small Cell Lung Cancer/Malignant Pleural Mesothelioma/Thymomas and Thymic Carcinomas Panel. She also contributes to the NCCN Oncology Research Program as a member of the Nintedanib Scientific Review Committee and the Sorafenib Steering Committee.

Eric Jonasch, MD, is Professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. Dr. Jonasch also serves as Director of the Von Hippel-Lindau (VHL) Clinical Center at MD Anderson and is Co-Director of the MD Anderson Kidney Cancer Research Program.

Dr. Jonasch received his medical degree from McGill Medical School in Montreal, Canada and completed his clinical residency in internal medicine at the Royal Victoria Hospital, also located in Montreal. He later completed a clinical fellowship in hematology/oncology at the New England Medical Center and a research fellowship at the Beth Israel Deaconess Medical Center.

Dr. Jonasch's clinical interests focus on tissue-based translational research in renal cell carcinoma and VHL disease. He heads a number of investigator-initiated clinical trials and ongoing laboratory research efforts in these disease states to evaluate the determinants of response and resistance to targeted therapies.

Dr. Jonasch is a member of multiple professional organizations, including the American Association for Cancer Research, the American Society of Clinical Oncology, and the VHL Alliance Board of Directors. He also serves as a reviewer for numerous journals, including *The New England Journal of Medicine*, the *Journal of Clinical Oncology*, the *Journal of Clinical Investigation*, and *Cancer Research*. He has authored or co-authored more than 100 peer-reviewed journal articles and numerous book chapters. He is editor of the textbook [Kidney Cancer, Principles and Practice](#).

Dr. Jonasch currently serves as Vice-Chair of the NCCN Kidney Cancer Panel and the NCCN Testicular Cancer Panel.

Jeffrey Jones, MD, MPH, is Associate Professor of Internal Medicine in the Division of Hematology at The Ohio State University School of Medicine, where he also directs the chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL) clinical research program.

Dr. Jones earned his medical degree from the University of Michigan Medical School and a master of public health degree in disease control from The University of Texas School of Public Health. He completed a medical oncology fellowship at The University of Texas MD Anderson Cancer Center.

Dr. Jones is a clinical investigator whose research interests include experimental therapeutics in CLL and HCL. He has authored or co-authored papers appearing prominent scientific publications, including *The New England Journal of Medicine*, the *Journal of Clinical Oncology*, *Blood*, *Leukemia*, and *Cancer*. Dr. Jones is a frequent lecturer both nationally and internationally.

Wui-Jin Koh, MD, is Professor of Radiation Oncology at University of Washington and Medical Director for Radiation Oncology at Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.

Dr. Koh earned his medical degree at Loma Linda University School of Medicine. He conducted his post-graduate training at the University of Washington Medical Center, completing a residency and internship in radiation oncology and a clinical fellowship in tumor imaging. He is board-certified in radiation oncology.

Dr. Koh's research interests include combined chemo-radiation strategies, cancer management guidelines development, and the role of imaging in radiotherapy and cancer care. He specializes in gynecologic tumors, lung cancer, ocular tumors, and sarcomas, as well as intraoperative radiotherapy, brachytherapy—including radioactive implants, high-dose radiation and low-dose radiation implants. He also treats rectal, esophageal, stomach, pancreas, colon, and biliary tract cancers.

Dr. Koh is well-published and involved in numerous professional societies, including the Society of Gynecologic Oncology, the American Society for Therapeutic Radiology and Oncology, the American Society of Clinical Oncology, the Gynecologic Oncology Group, the Western Association of Gynecologic Oncology, and the International Gynecologic Cancer Society.

Dr. Koh serves as co-Chair of the NCCN Cervical/Uterine Cancers Panel and is a member of the editorial board for the *Journal of the National Comprehensive Cancer Network (JNCCN)*.

Rogério Lilenbaum, MD, is Professor of Medicine at the Yale School of Medicine and Chief Medical Officer at the Smilow Cancer Hospital at Yale-New Haven.

Dr. Lilenbaum received his medical degree from the Federal University of Rio de Janeiro School of Medicine in Brazil and earned a master's degree in clinical epidemiology and clinical investigation from the Harvard School of Public Health. He completed a hematology/oncology fellowship at Washington University School of Medicine and a clinical and research fellowship at the University of California San Diego.

Dr. Lilenbaum served as a member of the Thoracic Malignancy Steering Committee of the National Cancer Institute and as the inaugural Chair of the Community Research Forum of the American Society of Clinical Oncology Cancer Research Committee. He served as a member of the Alliance Respiratory Core Committee and the RTOG Lung Committee, and is currently a member of the SWOG Lung Committee.

Among his awards and recognitions, Dr. Lilenbaum is consistently selected by *America's Top Physicians* and *America's Top Oncologists*. He has authored more than 100 peer-reviewed papers and book chapters on lung cancer and serves as a Section Editor for *UpToDate*.

Dr. Lilenbaum is a member of the NCCN Non-Small Cell Lung Cancer Panel and the NCCN Board of Directors.

Shirin Malekpour, PhD, is a mathematician and math educator at the University of Wisconsin-Madison.

Shirin, along with her family, cared for her mother, a pediatric hematologist/oncologist, who was diagnosed with advanced stage cancer in January of 2012. Shirin and her family feel very lucky and blessed that her mother chose palliative care and hospice care for last couple of months of her life.

Michelle Melisko, MD, is Associate Clinical Professor of Hematology/Oncology in the Department of Medicine at UCSF Helen Diller Comprehensive Cancer Center.

Dr. Melisko earned her medical degree from the Wake Forest University School of Medicine. She completed a residency in internal medicine at Stanford Hospital and Clinics and a fellowship in hematology and oncology at UCSF Medical Center.

Dr. Melisko is a cancer specialist with expertise in breast cancer treatment and research. Her clinical interests include testing new chemotherapy combinations, biological therapies, and immunotherapies for breast cancer, with a particular focus on the treatment of cancer that has spread to the brain. She is also the Medical Director of the UCSF Breast Cancer Survivorship Program and has led multiple trials investigating symptom management and follow up strategies for breast cancer patients. Through her work, Dr. Melisko hopes to educate patients and encourage their participation in clinical trials to make more rapid advances in breast cancer treatment.

Dr. Melisko is a member of the NCCN Survivorship Panel.

James Mohler, MD, is Associate Director for Translational Research and Senior Vice President, Chair of the Department of Urology, Co-leader of the Prostate Program, and Professor of Oncology at Roswell Park Cancer Institute. Dr. Mohler also serves as Professor of Urology at the University at Buffalo School of Medicine and Biomedical Sciences and Adjunct Professor of Urology and Member of UNC-Lineberger Comprehensive Cancer Center.

Dr. Mohler earned his medical degree from the Medical College of Georgia and completed residency training in surgery and urology at the University of Kentucky Medical Center and a research fellowship in urologic oncology at The Johns Hopkins University School of Medicine.

Dr. Mohler's clinical practice focuses on prostate cancer and robot-assisted laparoscopic surgery. His laboratory concentrates on the role of the androgen receptor in racial differences in prostate cancer aggressiveness and prostate cancer recurrence during androgen deprivation therapy. He has authored or co-authored more than 250 publications and book chapters as well as the book Androgen Action in Prostate Cancer.

Dr. Mohler serves on the editorial boards of several peer-reviewed publications, including the *Journal of the National Comprehensive Cancer Network (JNCCN)*, *The Prostate*, the *Journal of Robotic Surgery*, *Therapeutic Advances in Urology*, and *Hormones and Cancer*. He also has served as a reviewer for several other scientific journals, including *The New England Journal of Medicine*, the *Journal of Clinical Oncology*, and *Cancer*.

Dr. Mohler is a Diplomate of the National Board of Medical Examiners and the American Board of Urology and is a Fellow of the American College of Surgeons. He is Past-President of the Society for Basic Urologic Research. He is a member of the American Medical Association, the American Association for the Advancement of Science, the American Association for Cancer Research, the American Urological Association, and the American College of Surgeons.

Dr. Mohler is Chair of the NCCN Prostate Cancer Panel and a member of the NCCN Prostate Cancer Early Detection Panel. He also serves on the NCCN Guidelines Steering Committee and the NCCN Board of Directors.

Louis Burt Nabors, MD, is Vice-Chairman of Neurology, Professor, and Director of the Neuro-Oncology Program at the University of Alabama at Birmingham Comprehensive Cancer Center.

Dr. Nabors earned his medical degree from the University of Tennessee. He later completed an internship in medicine at the National Naval Medical Center in Bethesda, Maryland, as well as a residency in neurology and a fellowship in neuro-oncology at the University of Alabama at Birmingham. He served as a United States Navy Flight Surgeon on active duty from 1991–1995 and reserves from 1995–2002.

Dr. Nabors' research examines primary brain tumors, specifically focusing on the role of post-transcriptional regulation of gene expression, the acquisition and post-processing of magnetic resonance imaging data, and early phase clinical evaluation of novel cancer therapies.

Dr. Nabors is a member of the American Academy of Neurology, the American Society of Clinical Oncology, the American Neurological Association, and the Society for Neuro-Oncology. He also has served as an ad-hoc reviewer for multiple scientific journals and has authored or co-authored numerous journal articles, abstracts, and book chapters. He also serves on the editorial board for *Neuro Oncology*.

Dr. Nabors is Chair of the NCCN Central Nervous Systems Cancers Panel and an editorial board member for the *Journal of the National Comprehensive Cancer Network (JNCCN)*.

Joseph B. Narus, DNP, APRN, NP, is a nurse practitioner in the Male Sexual and Reproductive Medicine Program at Memorial Sloan Kettering Cancer Center. He joined Memorial Sloan Kettering Cancer Center in 2005 as the first nurse practitioner to manage the Penile Rehabilitation Program.

Dr. Narus earned his bachelor's, master's, and doctor of nursing practice degrees from New York University College of Nursing. He is the recipient of many prestigious honors and awards, including the Samuel and May Rudin Nursing Award for Excellence in Advanced Practice Nursing from Memorial Sloan Kettering Cancer Center and the Maes-McInnes Clinical Innovation Award from New York University College of Nursing.

Dr. Narus' main clinical and research focus is on sexual dysfunction following cancer treatment and the role of nursing to improve quality of life outcomes. Dr. Narus has lectured and presented abstracts at many professional meetings across the country. He is a member of several professional associations, including the American Association of Nurse Practitioners, the American Urologic Association, and the International Society of Sexual Medicine. Additionally, he is the first nurse practitioner to hold a Fellow membership with the Sexual Medicine Society of North America.

Kevin Oeffinger, MD, is Director of the Cancer Survivorship Center and Director of the Adult Long-Term Follow-Up Program at Memorial Sloan Kettering Cancer Center. He also serves as Co-Leader of the Memorial Sloan Kettering Cancer Center Survivorship, Outcomes, & Risk Program.

Dr. Oeffinger received his medical degree from the University of Texas Health Science Center at San Antonio. He continued his post-graduate training by completing a family medicine residency and a faculty development fellowship in family medicine at the McLennan County Medical Education and Research Foundation of Baylor College of Medicine in Waco, Texas.

Dr. Oeffinger's research focuses on investigating the long-term outcomes following cancer. Specifically, his work examines the etiology, mechanisms, risk factors, risk modeling, screening and surveillance, and risk-reducing interventions in second malignant neoplasms and cardiovascular disease, the two most common causes of death in cancer survivors.

As part of an initiative commissioned by the National Cancer Policy Board, Dr. Oeffinger provided a rationale for long-term follow-up healthcare of childhood cancer survivors and a theoretical model of the potential barriers and facilitators of care. The resulting report served as the background for the Institute of Medicine report, *Childhood Cancer Survivorship: Improving Care and Quality of Life* and has been integrated into the evolving models of healthcare for cancer survivors.

Dr. Oeffinger serves as a member of the Childhood Cancer Survivorship Study (CSSS) Executive Committee and chairs the CCSS Chronic Disease Working Group. He also is Chair of the American Society of Clinical Oncology Cancer Survivorship Committee and the Leukemia & Lymphoma Society Quality of Life Research Initiative. Additionally, Dr. Oeffinger is a member of the American Cancer Society Cancer Screening Guidelines Panel and chairs the Breast Cancer Screening Guidelines SubGroup. In these roles, Dr. Oeffinger led the multi-disciplinary panel that developed the 2015 breast cancer screening guideline for the American Cancer Society. He also serves on the editorial boards for several scientific publications, including *Cancer Epidemiology, Biomarkers and Prevention*, *Cardio-Oncology*, *Pediatric Blood and Cancer*, and the *Journal of Cancer Survivorship*.

Dr. Oeffinger is a member of the NCCN Adolescent and Young Adult Oncology Panel.

Judith Paice, PhD, RN, FAAN, is Director of the Cancer Pain Program in the Division of Hematology-Oncology and Research Professor of Medicine at the Feinberg School of Medicine at Northwestern University. She also is a full member of the Robert H. Lurie Comprehensive Cancer Center. She previously served as President of the American Pain Society and Secretary of the International Association for the Study of Pain.

Dr. Paice received her master's of science in oncology nursing from Rush University and a doctorate of philosophy in nursing science from the University of Illinois. Dr. Paice is a Certified Hospice and Palliative Nurse (CHPN) and an Advanced Practice Palliative Care Nurse (APPCN).

Much of Dr. Paice's clinical work focuses on managing and relieving pain associated with cancer and HIV disease. She has traveled widely within the People's Republic of China, Indonesia, Japan, Kenya, Korea, Kyrgyzstan, Russia, Taiwan, Tanzania, Tajikistan, and many other countries to educate health care professionals on cancer pain relief and palliative care.

Dr. Paice has authored more than 150 scientific manuscripts and serves on the editorial boards for the *Journal of Pain*, the *Clinical Journal of Pain*, and the *Journal of Pain and Symptom Management*. She was one of the original consultants in the End of Life Nursing Education Consortium (ELNEC) and has continued serving as a faculty member for the program.

Dr. Paice is a member of the NCCN Adult Cancer Pain Panel.

Tuya Pal, MD, is an associate member in the Department of Internal Medicine and Department of Cancer Epidemiology at Moffitt Cancer Center.

Dr. Pal earned her medical degree from McGill University in Montreal, Quebec. She completed a fellowship in clinical genetics at the Hospital for Sick Children/University of Toronto and a research fellowship in cancer genetics at the Women's College Research Institute, also located in Toronto.

Dr. Pal's research interests include epidemiologically-based studies focused on inherited cancer predisposition. Her research has spanned the cancer prevention and control continuums, with evaluations of genetic etiology, cancer risks and outcomes, including efforts to investigate the etiology of breast cancer in high-risk Black women. Additionally, she has investigated the delivery of genetic services, including issues related to identification and access to genetic services, as well as factors associated with quality of care. These efforts include the development of the Inherited Cancer Registry (ICARE) Initiative at Moffitt through which she has partnered with community practitioners to evaluate cancer risk management practices at both the patient and provider level.

Dr. Pal is a member of numerous professional societies and committees, including the American College of Medical Genetics and Genomics, the American Society of Clinical Oncology, and the American Association of Cancer Research. She has authored or co-authored a significant number of scientific publications and serves as a member of the National Cancer Institute's PDQ Cancer Genetics editorial board.

Kavita Patel, MD, is a Nonresident Senior Fellow at the Brookings Institution. She is also still a practicing primary care physician at the Johns Hopkins Community Physician Practice located at Sibley Hospital in Washington, D.C.

Her research and reports focused on patient-centered care, payment and delivery system reform, workforce issues, and health reform implementation. Her expertise earned her a regular expert commentary spot on radio and in print media, including National Public Radio, CBS, *Newsweek*, and *MarketWatch*.

Dr. Patel also served in the Obama Administration as Director of Policy for the Office of Intergovernmental Affairs and Public Engagement in the White House, where she played a key role in the design of health care reform legislation.

Dr. Patel also has a deep understanding of Capitol Hill from her time spent on the late Senator Edward Kennedy's staff. As Deputy Staff Director on Health, she served as a policy analyst and trusted aide to the Senator and was part of the senior staff of the Health, Education, Labor and Pensions (HELP) Committee under Senator Kennedy's Leadership.

In addition to these accomplishments, Dr. Patel serves on the board of several organizations including Dignity Health, Community Catalyst, and the National Initiative for Children's Healthcare Quality. She is also an advisor to HealthLoop, an emerging mobile technology company, as well as founding advisor of AVIA, a venture accelerator based in Chicago. She is also a World Economic Forum Young Global Leader.

Prior to Washington, Dr. Patel was a clinical instructor at UCLA and an Associate Scientist at the RAND Corporation. She completed a fellowship in the Robert Wood Johnson Clinical Scholars Program at UCLA and received her medical training at the University of Texas Health Science Center and Oregon Health and Sciences University where she served as Chief Resident in Internal Medicine.

Barbara Pro, MD, is Professor of Medicine in the Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine, where she also serves as Director of the Northwestern Medicine Developmental Therapeutics Institute's Fellowship Program. Dr. Pro previously worked at Thomas Jefferson University-Kimmel Cancer Center where she served as Professor of Medical Oncology and Chief of the Lymphoma Section and Director of the Multidisciplinary Cutaneous Lymphoma Clinic. She previously held faculty positions at MD Anderson Cancer Center and Fox Chase Cancer Center.

Dr. Pro received her medical degree from University La Sapienza in Italy. She completed a fellowship in medical oncology at University La Sapienza, followed by an internship, fellowship, and chief residency in internal medicine at The Mount Sinai School of Medicine. She also completed a medical oncology fellowship at the University of Texas MD Anderson Cancer Center.

Dr. Pro is a distinguished scholar and national leader in the research and treatment of Hodgkin and non-Hodgkin lymphomas, specializing in T-cell lymphoma. As a clinical researcher, Dr. Pro works to improve treatment options and outcomes for patients affected by lymphoproliferative disorders. Her clinical research on the application of targeted therapeutic agents for the treatment of aggressive lymphoma subtypes has led to the approval of several novel drugs.

Dr. Pro has received won several professional awards, including *Best Doctors*, *America's Top Oncologists*, and *US News Top Doctors*, and has been published in several prominent journals, including *Blood*, the *Journal of Clinical Oncology*, *Annals of Oncology*, *Clinical Cancer Research*, and the *British Journal of Hematology*. She currently serves as member of numerous professional organizations, including the Italian Association of Medical Oncology, the American College of Physicians, the American Society of Clinical Oncology, the American Society of Hematology, the European Association for Cancer Research, and the Italian Society of Immunology, Oncology and Embryology.

Jerald P. Radich, MD, is a member of the Clinical Research Division and Director of the Molecular Oncology Lab at the Fred Hutchinson Cancer Research Center and Professor of Medicine at the University of Washington School of Medicine.

Dr. Radich earned a master's of science degree in epidemiology at Harvard University School of Public Health before attending University of California, Davis, School of Medicine. He completed both his internship and residency in internal medicine at University of Washington Affiliated Hospitals before accepting a position as chief medical resident at the Veterans Administration Medical Center Affiliated Hospitals in Seattle, Washington. Dr. Radich then took a fellowship in medical oncology at Fred Hutchinson Cancer Research Center, where he subsequently has remained.

Dr. Radich's main research interest concerns the genetics of leukemia and the use of modern molecular biology techniques toward the early detection of cancer. He is Chair of the Leukemia Translational Medicine Committee of the Southwest Oncology Group, Co-Chair of the NCI/NIH Leukemia Steering Committee, and a member of the European LeukemiaNet (ELN) Chronic Myeloid Leukemia Panel.

Dr. Radich serves as Chair of the NCCN Chronic Myelogenous Leukemia Panel and is a member of the editorial board for the *Journal of the National Comprehensive Cancer Network (JNCCN)*.

Ashley Ross, MD, PhD, is Assistant Professor in the Departments of Urology, Oncology, and Pathology and Director of the Johns Hopkins Urology Prostate Cancer Program at the Johns Hopkins School of Medicine. He also is an active member of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, where he leads clinical trials exploring novel therapeutic and diagnostic approaches for prostate cancer.

Dr. Ross received his doctorate of philosophy in biochemistry and medical degree from the Johns Hopkins University School of Medicine. He completed a general surgery internship, followed by a urology residency and fellowship at Johns Hopkins Medical Institution.

Dr. Ross specializes in the treatment of benign prostatic hyperplasia, bladder cancer, prostate cancer, and urology. His research interests include prostate cancer active surveillance, robotic and open surgical approaches for the treatment of disease, multi-disciplinary approaches to aggressive prostate cancer, and the management of recurrent disease after radiation therapy. His laboratory investigates molecular mechanisms that drive prostate cancer and is developing and testing novel targeted therapies for this aggressive disease. His team is striving to develop and evaluate molecular tests which may guide individualized diagnostic and treatment selections for patients.

Dr. Ross has been recognized with numerous awards and honors, including the Johns Hopkins Clinical Scientist Award and the Department of Defense Prostate Cancer PTR A Award. Dr. Ross is a member of the American Urologic Association and an associate editor of *Prostate Cancer Prostatic Diseases* and the *Annals of Surgical Oncology*.

Kilian E. Salerno, MD, is Assistant Professor of Radiation Oncology and Director of Breast Radiation and Soft Tissue/Melanoma Radiation at Roswell Park Cancer Institute.

Dr. Salerno received her medical degree from the School of Medicine and Biomedical Sciences at the State University of New York at Buffalo, where she also completed residencies in emergency medicine and radiation oncology.

Dr. Salerno specializes in the treatment of breast and soft tissue/skin cancers. Her work has been published in several scientific journals, including the *International Journal of Radiation Oncology, Biology, Physics*, the *Journal of Surgical Oncology*, the *Annals of Surgical Oncology*, and the *Journal of the National Comprehensive Cancer Network (JNCCN)*.

Dr. Salerno is a member of the American Society of Clinical Oncology Postmastectomy Radiation Guidelines Panel and the NCCN Breast Cancer Panel.

Marc Samuels, JD, MPH, is CEO and founder of ADVI, a Washington, D.C.-based healthcare consulting firm specializing in policy, strategy, and commercial development for life science and healthcare services companies and organizations.

Prior to ADVI, Mr. Samuels was a partner in HillCo Partners and a founder of Hillco Health. Earlier he served both President George H.W. Bush and President George W. Bush (when he was Texas Governor) in the White House Office of Policy Development and Governor's Policy Office, respectively. Mr. Samuels last served as Chief of Staff to Texas Health and Human Services Commission before leaving government altogether to join the private sector.

Mr. Samuels has published and spoken widely in peer-reviewed and professional journals on topics in healthcare policy and business. His comments and analyses have appeared in *In Vivo*, *Journal of Oncology Practice*, *Medical Economics*, *Health Systems Review*, *Journal of Health Care Finance*, *Disease Management News*, *the Fort Worth Star-Telegram*, *the Dallas Morning News*, and *Texas Medicine*. He is a contributor to the third edition of the Managed Care Answer Book and the second edition of the HMO and Capitation Answer Book, published by Panel Publishers, New York.

Mr. Samuels is a graduate of The University of Texas School of Law, Yale School of Medicine, and the University of Michigan.

Mr. Samuels is a member of the NCCN Foundation Board of Directors.

Lee Schwartzberg, MD, is Executive Director of West Cancer Center and Senior Partner and Medical Director at The West Clinic, a regional oncology, hematology, and radiology practice located in Memphis, Tennessee. Dr. Schwartzberg also serves as Professor of Medicine and Division Chief of Hematology/Oncology at The University of Tennessee Health Science Center. Additionally, he is President/CMO for Vector Oncology, an oncology specific SMO/CRO.

Dr. Schwartzberg received his medical degree from New York Medical College. After completing his internal medicine residency at Cornell University/North Shore University Hospital, Dr. Schwartzberg continued his training with a medical oncology and hematology fellowship at Memorial Sloan Kettering Cancer Center, where he also served as Chief Medical Resident and was a founding member of the institutional ethics committee.

Dr. Schwartzberg's specializes in the treatment of breast cancer, with a specific research focus on new therapeutic approaches, targeted therapy, and supportive care. Dr. Schwartzberg has published more than 150 peer reviewed articles in peer-reviewed journals, including the *Journal of Clinical Oncology*, *Lancet Oncology*, and *Annals of Oncology*.

Dr. Schwartzberg was the founding editor-in-chief of the journal *Community Oncology* and currently serves as the Editor-in-Chief of the *Practice Update Oncology* website. He serves on the editorial boards for both the *Journal of Supportive Oncology* and *The ASCO Post*, in addition to serving as a reviewer for many prominent medical journals, including *The New England Journal of Medicine* and the *Journal of Clinical Oncology*.

Dr. Schwartzberg serves on the NCCN Board of Directors and the NCCN Guidelines Steering Committee. He also is a member of the NCCN Breast Cancer Panel and the NCCN Myeloid Growth Factors Panel. Additionally, Dr. Schwartzberg serves as a member of the NCCN Oncology Research Program Investigator Steering Committee and the Young Investigator's Award Review Committee.

Carri Siedlik, APRN, ACHPN, is a Nurse Practitioner in the Palliative Care Program at the University of Nebraska Medical Center, Fred & Pamela Buffett Cancer Center. She previously served as an instructor in the Adult Health and Illness Department in the University of Nebraska Medical Center's College of Nursing.

Ms. Siedlik earned her undergraduate nursing degree from the University of Nebraska Medical Center-Lincoln and her adult nurse practitioner degree from the University of Missouri-Kansas City.

As a palliative care clinician, Ms. Siedlik works with multiple students in both the nursing and medicine programs. She also serves as a mentor to advanced practice nurses, residents, palliative care fellow and hospital staff.

Ms. Siedlik is a member of numerous professional societies and associations including the American Nurses Association, Nebraska Hospice and Palliative Care Association, and the Hospice and Palliative Nurses Association.

Mary Lou Smith, JD, MBA, is Co-Founder of the Research Advocacy Network. Ms. Smith was formerly Director of Patient, Payer, and Government Relations for the Coalition of Cancer Cooperative Groups. Ms. Smith also is Past President of the Y-ME National Breast Cancer Organization and a two-time breast cancer survivor and an ovarian cancer survivor.

Ms. Smith has a juris doctorate with a health law certificate and a master's of science degree in business administration. She has spent over 20 years dedicated to the healthcare industry.

Before her tenure with the Coalition of Cancer Cooperative Groups, Ms. Smith developed managed care products for the Blue Cross and Blue Shield Association. These products included a “centers of excellence” network for pediatric oncology, a women’s service initiative, a clinical trials program, a case management network, and a national second opinion consulting program.

Ms. Smith currently serves as Co-Chair of the ECOG-ACRIN Cancer Research Advocacy Committee and as Board Member and Chair of the Advocacy and Outreach Committee for the National Accreditation Program for Breast Centers. She also serves as a member of the Gateway for Cancer Research Board of Directors, the NCI Board of Scientific Advisors, and the NCI BOLD Task Force.

Ms. Smith serves as the patient advocate representative on the NCCN Breast Cancer Panel and the NCCN Breast Cancer Screening and Diagnosis Panel.

Sophia Smith, PhD, MSW, is Associate Professor in the School of Nursing at Duke University. She previously served as a Research Scientist in the Cancer Care Research Program and Center of Learning Health Care at the Duke Clinical Research Institute.

Dr. Smith earned her doctorate of philosophy and master’s of social work degree at the University of North Carolina School of Social Work. Her clinical background includes social work internships in pediatric hematology/oncology at the Duke Comprehensive Cancer Center and the Hospice of Alamance County. Also, Dr. Smith has a personal history as a two-time cancer survivor which provides a unique perspective of the complexities of patient care from both the patient and healthcare provider perspectives. Prior to beginning her career in oncology social work, Dr. Smith was a senior manager at IBM and led an organization of computer application programmers and systems analysts.

Dr. Smith’s research has focused on innovative mobile health intervention and psychosocial care solutions to improve health outcomes for cancer survivors. Her work has helped to define the longitudinal quality of life and patient experience of survivors of adult lymphoma, with a particular focus on posttraumatic stress disorder, the impact of cancer, and implementation of evidence-based supportive care services.

Dr. Smith is a member of the NCCN Survivorship Panel.

Michael B. Streiff, MD, is Associate Professor of Medicine at The Johns Hopkins University School of Medicine, Johns Hopkins Hospital, and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He also serves as Medical Director of the Johns Hopkins Anticoagulation Management Service and Outpatient Clinics as well as Staff Physician at Johns Hopkins Comprehensive Hemophilia Treatment Center.

Dr. Streiff received his medical degree from Johns Hopkins University School of Medicine. He completed an internship and residency in internal medicine at the University of Florida and a fellowship in hematology/oncology at The Johns Hopkins University.

Dr. Streiff's clinical and research interests focus on the prevention and treatment of venous thromboembolism and the management of anticoagulation, hemophilia, and other coagulation disorders. He has published more than 100 articles and book chapters in scientific journals such as the *Journal of the American Medical Association*, the *Journal of Clinical Oncology*, *Blood*, the *British Medical Journal*, *The American Journal of Medicine*, and *Cancer*. Additionally, he has served on international consensus panels to develop standardized guidelines for the use of vena caval filters in the management of venous thromboembolism.

Dr. Streiff is Chair of the NCCN Cancer-Associated Venous Thromboembolic Disease Panel and a member of the editorial board for the *Journal of the National Comprehensive Cancer (JNCCN)*.

John A. Thompson, MD, is the Medical Director of the Phase I Clinical Trials Program and Co-Director of the Melanoma Clinic at the Seattle Cancer Care Alliance. He also serves as a professor in the Medical Oncology Division at the University of Washington School of Medicine and is a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center.

Dr. Thompson received his medical degree from the University of Alabama at Birmingham. He completed his internship and residency in internal medicine and his fellowship in oncology at the University of Washington. Dr. Thompson is board-certified in internal medicine and medical oncology.

Dr. Thompson is a member of several medical societies, including the American Society of Clinical Oncology, the American Association for Cancer Research, the Society for Immunotherapy of Cancer, and the National Kidney Cancer Association. He has authored or co-authored more than 150 articles, appearing in publications such as the *Journal of Immunology*, *Blood*, *Leukemia*, the *Journal of Clinical Oncology*, and *Bone Marrow Transplantation*.

Dr. Thompson is Vice-Chair of the NCCN Melanoma Panel. He has served on several committees for the NCCN Oncology Research Program, including the NCCN GSK BRAF and MEK Scientific Review Committees and the NCCN Sunitinib Preclinical Advisory Board, Project Advisory Team, and Scientific Review Committee.

Peter A. Ubel, MD, is the Madge and Dennis T. McLawhorn University Professor of Business, Public Policy, and Medicine at Duke University. He is core faculty at the Duke-Margolis Center for Health Policy.

Dr. Ubel received his medical degree from the University of Minnesota-Twin Cities. He completed an internal medicine residency at Mayo Graduate School of Medicine in Rochester, Minnesota, followed by a medical ethics fellowship at the University of Chicago and a general medicine fellowship at the University of Pittsburgh.

As a physician and behavioral scientist, Dr. Ubel explores how people make decisions related to health and health care. His research focuses on the role of values and preferences in health care decision making, from decisions at the bedside to policy decisions. Using decision psychology and behavioral economics, Dr. Ubel explores topics like informed consent, shared decision making, and health care cost containment.

Dr. Ubel is a prolific writer. He has authored over 250 academic publications, the majority of which involve empirical explorations of decision psychology as it pertains to health care. He is a regular contributor to *Forbes* and also has written for *The New York Times*, *The Los Angeles Times*, *The Atlantic*, and *The New Yorker*. In addition to his online publications accessible at www.peterubel.com, his published books include [Pricing Life](#), [Free Market Madness](#), and [Critical Decisions](#).

Alan P. Venook, MD, is the Madden Family Distinguished Professor of Medical Oncology and Translational Research and serves as Chief of the Gastrointestinal Oncology Clinical Program at the University of California, San Francisco (UCSF). Dr. Venook also is the Shorenstein Associate Director of Program Development at the UCSF Helen Diller Family Comprehensive Cancer Center.

Dr. Venook received his medical degree from the UCSF School of Medicine. Following his internship, he spent two years in the Public Health Service and completed an internal medicine fellowship at UC Davis and a hematology/oncology fellowship at UCSF.

A nationally recognized expert in colorectal and liver cancers, Dr. Venook is an associate editor of the *Journal of Clinical Oncology*. His written work on gastrointestinal malignancies has been widely published in scholarly articles, chapters, and textbooks.

Dr. Venook is an active member of the American Society of Clinical Oncology (ASCO). He recently served as Chair-elect of the ASCO 2015 Scientific Program and as a member of the ASCO Government Relations Committee. He formerly chaired the National Cancer Institute (NCI) Hepatobiliary Task Force and currently chairs the Gastrointestinal Committee of the Alliance for Clinical Trials in Oncology, where he oversees an extensive clinical trial portfolio. Dr. Venook is a member of the Colon Cancer Task Force as well as the NCI Gastrointestinal Cancer Steering Committee.

Dr. Venook serves on the NCCN Board of Directors, International Program Steering Committee, and IRB Directors Forum. He also is a member of the NCCN Hepatobiliary Cancers Panel and the NCCN Colon/Rectal/Anal Cancers Panel and contributes to a several committees, advisory boards, and teams affiliated with the NCCN Oncology Research Program.

Christopher Willett, MD, is Professor and Chairman of the Department of Radiation Oncology at Duke University Medical Center and a member of Duke Cancer Institute.

Dr. Willett earned his medical degree from Tufts University Medical School. He completed a surgical internship at Vanderbilt University Medical Center, followed by a radiation oncology residency and fellowship at Massachusetts General Hospital.

Dr. Willett specializes in gastrointestinal malignancies and is involved in clinical trials that examine novel agents combined with standard radiation therapy and chemotherapy. His clinical research also examines new imaging modalities to better define tumors both anatomically and functionally. The goal of these studies is to improve patients' outcomes and quality of life and to determine the usefulness of treatments during therapy.

Dr. Willett is author or co-author of nearly 174 peer review publications and 269 other scientific publications. Additionally, he is an ad-hoc reviewer for various scientific journals and serves on the editorial boards of *International Journal of Radiation Oncology, Biology, and Physics*, the *Journal of Clinical Oncology*, and the *Annals of Surgical Oncology*. He also is a member of numerous professional and scientific societies.

Dr. Willett is a member of the NCCN Colon/Rectal/Anal Cancers Panel and the NCCN Esophageal/Gastric Cancers Panel.

Andrew D. Zelenetz, MD, PhD, is Vice Chair, Medical Informatics in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSKCC) in New York. Prior to that, he had held the position of Chief of the Lymphoma Service in the Division of Hematology/Oncology at MSKCC from 1994-January, 2013. He also is Professor of Medicine at Weill Medical College of Cornell University.

Dr. Zelenetz has helped develop a number of the agents now approved to treat lymphoma — including 131I-tositumab/tositumomab, bortezomib, and pralatrexate — and, through clinical studies, he is evaluating the benefits of novel combinations of agents. In another area of research, he is working to improve the prognostic value of patients' pathology specimens using computer-aided image analysis. He has published more than 100 papers on lymphoma research in journals such as *Blood*, the *Journal of Clinical Oncology*, and *Clinical Cancer Research*.

Dr. Zelenetz received his bachelor of arts degree from Harvard College; his doctorate of philosophy from Harvard University's Graduate School of Arts and Sciences, Division of Medical Sciences; and his medical degree from Harvard Medical School. Both his internship and residency in medicine were completed at Stanford University Medical Center as well as a clinical fellowship and research fellowship in oncology.

Dr. Zelenetz is a member of the American Society of Hematology, the American Society of Clinical Oncology and the American College of Physicians. He participates in various committees: he is Vice Chairperson of the Cancer and Leukemia Group B Lymphoma Core Committee, Chair of the NCCN Non-Hodgkin's Lymphomas Panel, Board Member of the Leukemia and Lymphoma Society, and member of the Lymphoma Research Foundation Scientific Advisory Board. He has been the recipient of the Memorial Sloan Kettering Fellowship Teaching Excellence Award multiple times and has received the Rodger Winn Award from NCCN in 2012.
